


BioMarin reports a serious adverse event for its phase I/II gene therapy trial for haemophilia A
February 4, 2022 – BioMarin’s gene therapy (valoctocogene roxaparvovec) for haemophilia A is currently in development and not yet licensed by regulators. BioMarin has completed dosing 134 patients in its phase 3 clinical study...

FDA places the Pfizer/Sangamo Therapeutics phase 3 AFFINE haemophilia A gene therapy study on clinical hold

EHCucate goes live

European principles for women and girls with bleeding disorders published
WFH and EHC sign MoU

EHC is looking for a public policy and communications officer to join our team!

Take-aways from the EHC webinar on Women and Bleeding Disorders

Join the EHC for #thisway campaign in 2021!
